ArticleRSC advances2018
Biodistribution and targeting potential assessment of mucoadhesive chitosan nanoparticles designed for ulcerative colitis
Article in RSC advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 56 citations in OpenAlex.
- Review
- Development and Characterization of Celecoxib-Loaded Soluplus/Zein Composite Nanoparticles Coated with Chitosan for Pulmonary Drug Delivery.ACS omega · 2026Article
- Review
- Oridonin-Loaded PDA@Gel@GO Nanocapsules Modulate NLRP3 and Epithelial Repair in Colitis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Curcumin for inflammatory bowel disease therapy: advances in mechanisms, clinical applications, and drug delivery.Archives of pharmacal research · 2025Review
- Research advances in nanomaterials with aromatic functional groups for the treatment of inflammatory bowel disease.Frontiers in bioengineering and biotechnology · 2025Review
- Localized Drug Delivery in Different Gastrointestinal Cancers: Navigating Challenges and Advancing Nanotechnological Solutions.International journal of nanomedicine · 2025Review
- Vitamin E nanoparticles enhance performance and immune status of Nile tilapia.BMC veterinary research · 2024Article
- Chitosan-Based Nanoformulations: Preclinical Investigations, Theranostic Advancements, and Clinical Trial Prospects for Targeting Diverse Pathologies.AAPS PharmSciTech · 2024Review
- A blend of chitosan-vitamin C and vitamin E nanoparticles robust the immunosuppressed- status in Nile tilapia treated with salt.BMC veterinary research · 2024Article
- Dietary nanocomposite of vitamin C and vitamin E enhanced the performance of Nile tilapia.Scientific reports · 2024Article
- Combined ROS Responsive Polydopamine-Coated Berberine Nanoparticles Effective Against Ulcerative Colitis in Mouse Model.International journal of nanomedicine · 2024Article
- Achillea wilhelmsii-Incorporated Chitosan@Eudragit Nanoparticles Intended for Enhanced Ulcerative Colitis Treatment.AAPS PharmSciTech · 2023Article
- Biodistribution and Adjuvant Effect of an Intranasal Vaccine Based on Chitosan Nanoparticles against Paracoccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2023Article
- Article
- Article
- Evaluation of Recent Intranasal Drug Delivery Systems to the Central Nervous System.Pharmaceutics · 2022Review
- Colon-specific delivery of isoliquiritigenin by oral edible zein/caseate nanocomplex for ulcerative colitis treatment.Frontiers in chemistry · 2022Article
- Chitosan Nanoparticles at the Biological Interface: Implications for Drug Delivery.Pharmaceutics · 2021Review
- Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease.Chinese medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present investigation we have prepared and characterized curcumin (CN)-containing chitosan nanoparticles (CS-NPs) coated with Eudragit FS 30D for colon-specific drug delivery for treatment of ulcerative colitis.
methodsCS-NPs were prepared by ionic gelation using tripolyphosphate. To specify pH sensitive delivery, CS-CN-NPs were coated with Eudragit FS 30D by using a solvent evaporation method. Different process parameters were evaluated, and the optimized formulation was characterized by particle size, size distribution, zeta potential and encapsulation efficiency before lyophilization. The lyophilized product was further subjected to Fourier-transform infrared spectroscopy, and particle morphology and
resultsthe kinetics of
conclusionsustained and pH stimulated delivery of CN to the colon was successfully attained
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.